Subsequently, promising compounds would advance to in cellular assays using gastric cancer cell lines with well-defined genetic backgrounds (e.g., HER2-amplified, FGFR2b-amplified) to confirm on-target pathway modulation (e.g., inhibition of downstream AKT and ERK phosphorylation) and assess anti-proliferative effects. The gene discussed is ERBB2; the disease is gastric cancer.